Valuation: Lipella Pharmaceuticals Inc.

Market Cap 832K 731K 681K 625K 1.17M 79.76M 1.19M 8.09M 3.16M 39.39M 3.12M 3.06M 136M P/E 2023
-1.32x
P/E 2024 -0.64x
Enterprise Value -1.31M -1.15M -1.07M -981K -1.84M -125M -1.87M -12.7M -4.96M -61.82M -4.9M -4.8M -214M EV / Sales 2023
6.14x
EV / Sales 2024 2.89x
Free-Float
93.69%
Yield 2023 *
-
Yield 2024 -
07-14 An undisclosed buyer agreed to acquire Substantially all of the assets of Lipella Pharmaceuticals Inc from Lipella Pharmaceuticals Inc. for $3.4 million. CI
03-30 Lipella Pharmaceuticals Inc. files voluntary petitions for relief under Chapter 11 RE
03-30 Lipella Pharmaceuticals Inc. Filed for Bankruptcy CI
02-04 Lipella Pharmaceuticals Inc. Announces Resignation of Director Lori A. Birder, Effective February 3, 2026 CI
11-14 Lipella Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025 CI
25-10-09 Lipella Pharmaceuticals Inc. Announces Retirement of Michael Chancellor as Chief Medical Officer and Member of the Board of Directors, Effective December 4, 2025 CI
25-09-18 Lipella Pharmaceuticals Announces Positive Final Results from Phase 2a Study of LP-10 in Oral Lichen Planus CI
25-09-18 Lipella Pharmaceuticals announces positive final results from Phase 2a study of LP-10 in oral lichen planus RE
25-08-14 Lipella Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025 CI
25-06-23 Lipella Pharmaceuticals Inc.(NasdaqCM:LIPO) dropped from S&P TMI Index CI
25-06-18 Lipella Pharmaceuticals Inc.(OTCPK:LIPO) dropped from NASDAQ Composite Index CI
25-06-04 Lipella Pharmaceuticals Inc. Re-Signs Manufacturing Collaboration Agreement with Cook MyoSite Inc. to Support LP-310 Clinical Development CI
25-05-15 Lipella Pharmaceuticals to Present Phase 2A Data for LP-310 in Oral Lichen Planus at 2025 AAOM/EAOM International Meeting CI
1 day-49.38%
Current month-71.49%
1 month-63.67%
3 months+6.51%
6 months-81.53%
Current year-81.83%
1 month 0.03
Extreme 0.0327
0.13
Current year 0.02
Extreme 0.0197
0.32
1 year 0.02
Extreme 0.0197
0.78
3 years 0.02
Extreme 0.0197
21.68
5 years 0.02
Extreme 0.0197
61.76
10 years 0.02
Extreme 0.0197
61.76
Manager TitleAgeSince
Chief Executive Officer 60 2004-12-31
Director of Finance/CFO 42 2021-09-30
Chief Tech/Sci/R&D Officer - 2021-07-31
Director TitleAgeSince
Chairman 60 2004-12-31
Director/Board Member 55 2022-02-28
Director/Board Member 53 2021-08-31
Date Insider Type Main position Quantity % Market Cap.
4/3/25 Others

Chief Executive Officer

695,776 27.2981%
3/13/25 Others

Chief Executive Officer

14,386 0.5644%
3/10/25 Others

Chief Executive Officer

28,924 1.1348%
Change 5-day change 1-year change 3-year change Capi.($)
-49.38%0.00%-94.78%-99.81% 151K
-1.82%+4.80%+54.32%+68.36% 57.28B
-0.27%+5.74%+40.26%+80.17% 54.99B
-1.48%-1.51%+3.59%+416.69% 23.18B
+2.80%-0.35%-18.57%-12.53% 22.59B
-1.13%+4.54%+22.73%-8.06% 20.46B
+1.57%+3.30%+27.41%-29.07% 17.56B
-0.10%+5.57%+38.63%+565.16% 15.67B
+5.29%0.00%+185.09%+332.66% 14.46B
+1.16%+1.09%+26.46%+186.40% 13.92B
Average -4.35%+1.45%+28.51%+150.00% 24.01B
Weighted average by Cap. +0.01%+1.93%+39.92%+138.62%

Financials

2023 2024
Net sales 450K 395K 368K 338K 634K 43.12M 643K 4.37M 1.71M 21.29M 1.69M 1.65M 73.59M 536K 472K 439K 403K 757K 51.44M 767K 5.22M 2.04M 25.4M 2.01M 1.97M 87.79M
Net income -4.62M -4.06M -3.78M -3.47M -6.52M -443M -6.6M -44.93M -17.55M -219M -17.34M -16.97M -756M -5.02M -4.41M -4.1M -3.77M -7.08M -481M -7.17M -48.79M -19.06M -238M -18.83M -18.42M -821M
Net Debt -3.16M -2.78M -2.58M -2.37M -4.46M -303M -4.51M -30.71M -11.99M -150M -11.85M -11.6M -517M -2.14M -1.88M -1.75M -1.61M -3.02M -205M -3.06M -20.79M -8.12M -101M -8.02M -7.85M -350M
Logo Lipella Pharmaceuticals Inc.
Lipella Pharmaceuticals Inc. was a clinical-stage biotechnology company. The Company is no longer in operation and does not have any business activities.
Employees
6
Date Price Change Volume

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. LIPO Stock